Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 3.5% – Here’s What Happened

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price rose 3.5% during mid-day trading on Friday . The stock traded as high as GBX 1,045 and last traded at GBX 1,010. Approximately 27,761 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 60,900 shares. The stock had previously closed at GBX 976.

Hemogenyx Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The stock has a 50-day moving average price of GBX 1,044.44 and a 200-day moving average price of GBX 476.09. The company has a market capitalization of £54.15 million, a price-to-earnings ratio of -4.37 and a beta of 3.14.

Hemogenyx Pharmaceuticals (LON:HEMO) last posted its quarterly earnings results on Tuesday, September 30th. The company reported GBX (0.83) earnings per share for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.